b-Hydroxyisovalerate Test

Biotin is a B vitamin most people assume they have plenty of. The trouble is that subtle, low-grade biotin shortfalls are surprisingly common, especially during pregnancy and with certain gut conditions, and the most widely available test for biotin (a direct blood measurement) is not very good at catching them.

Measuring β-hydroxyisovalerate (3-hydroxyisovaleric acid) in urine takes a different angle. Instead of trying to measure biotin itself, this test captures a downstream byproduct that quietly accumulates when biotin runs low, giving you a more sensitive read on whether one of your body's protein-handling pathways has enough of the vitamin it needs.

What This Marker Actually Reflects

β-hydroxyisovalerate (β-HIV) is an intermediate in the breakdown of leucine, one of the amino acids in dietary protein. To move leucine through this pathway, your cells use a biotin-dependent enzyme called β-methylcrotonyl-CoA carboxylase. When biotin supply is adequate, the pathway runs smoothly and very little β-HIV is left over to spill into urine.

When biotin is low, the enzyme cannot keep up. Leucine breakdown stalls, β-HIV accumulates, and your kidneys clear the excess into urine. The number on this test, in other words, is a chemical fingerprint of how well one specific biotin-dependent reaction is running in your body.

The Biotin Connection

The strongest body of evidence behind this marker comes from controlled human studies of biotin deficiency. In a classic experimental study, 10 healthy adults were placed on an egg-white diet (raw egg whites contain a protein that blocks biotin absorption). Urinary β-HIV rose as biotin status dropped, and it rose earlier and more reliably than blood biotin levels, which barely budged. This is a key reason the marker exists: it catches insufficiency that direct biotin testing misses.

A leucine challenge (eating a large dose of leucine and then measuring β-HIV in urine) amplifies this signal. In 11 adults studied during marginal biotin deficiency, the leucine challenge produced a sharp rise in urinary β-HIV that was not seen when biotin status was normal. The pathway can compensate when biotin is sufficient, but starts to leak under load when it is not.

Pregnancy and Biotin Status

Pregnancy quietly increases biotin demand, and many women develop a low-grade deficiency without any obvious symptoms. In a randomized trial of 26 pregnant women with elevated urinary β-HIV, those given biotin supplementation showed a significant reduction in β-HIV compared to placebo. This is one of the few interventional trials where biotin was directly shown to move the number, and it makes β-HIV a useful way to flag and follow biotin status during pregnancy.

Gut Conditions and Absorption

Biotin deficiency also appears more often in people with inflammatory bowel disease (IBD), where absorption from the small intestine can be impaired. A study of 138 patients with IBD compared to 80 healthy controls found that biotin deficiency was more common in IBD and could be tracked using a related serum marker, 3-hydroxyisovaleryl-carnitine (a different but related molecule produced in the same pathway). The clinical pattern is consistent: when gut absorption falters, biotin-dependent enzymes start to underperform, and metabolites like β-HIV begin to accumulate.

Rare Inherited Metabolism Conditions

On the extreme end, very high urinary β-HIV is the hallmark of inherited disorders of leucine metabolism. A landmark case described an infant who excreted massive amounts of β-HIV in urine due to a genetic deficiency of the same biotin-dependent enzyme that biotin supports. Restricting dietary leucine sharply reduced β-HIV excretion. Adults will not see anything close to those numbers, but the case illustrates how directly β-HIV reflects the health of this specific pathway.

Emerging Research on Other Outcomes

Two recent genetic studies have hinted that higher circulating β-HIV may track with lower risk of certain neurological and autoimmune conditions. A Mendelian randomization analysis (a statistical method that uses genetic variation to test cause-and-effect) found that genetically higher β-HIV was associated with lower odds of myasthenia gravis, an autoimmune neuromuscular disease. A separate analysis found a similar protective link with traumatic brain injury susceptibility.

These findings come from blood-based measurements (not the dried urine specimen this test uses) and are exploratory. They suggest that β-HIV may sit at a crossroads between gut microbes, B-vitamin metabolism, and immune signaling, but they do not yet translate into clinical thresholds or treatment decisions. Treat them as background context, not a reason to act on a single result.

Reference Ranges

β-hydroxyisovalerate is a research and exploratory marker. There are no universally standardized clinical cutpoints, and most published studies use change from baseline rather than fixed thresholds. The ranges below are illustrative orientation drawn from biotin-deficiency research, not formal clinical targets, and they vary by lab, assay, and how the result is normalized to creatinine. Your lab will likely report different numbers.

Compare your results within the same lab over time for the most meaningful trend. A single number tells you very little; the trajectory tells you almost everything.

When Results Can Be Misleading

• Recent high-leucine meals: a large dose of leucine (think a big protein shake or steak the night before) can transiently push β-HIV upward for hours. This is the basis of the deliberate leucine-challenge test and does not reflect chronic biotin status.
• Pregnancy itself: baseline β-HIV rises in many pregnant women without any pathology. Interpret pregnancy results in that context rather than against non-pregnant ranges.
• Collection errors with dried urine: improper drying, contamination, or mismatched collection times can distort the creatinine-normalized result. Follow the timing and handling instructions precisely.
• Kidney function: because β-HIV is normalized to urinary creatinine, significantly altered kidney function or muscle mass can shift the ratio without reflecting a real change in metabolism.

Tracking Your Trend

A single β-HIV reading is a snapshot. What matters more is the direction it moves over time and how it responds to changes you make. Get a baseline measurement. If it is elevated and you start biotin supplementation or address an underlying absorption issue, retest in 8 to 12 weeks to confirm the number is coming down. If you are pregnant or have a condition that affects nutrient absorption, retest at least every 6 to 12 months to track status. For everyone else, annual retesting is reasonable as part of a broader metabolic or hormone workup.

What to Do With Your Result

An elevated β-HIV is not a diagnosis on its own. The most useful next step is to look at the rest of your B-vitamin and organic acid markers in context: methylmalonate (a B12 status marker), xanthurenate and kynurenate (B6 markers), and a full serum B-vitamin panel. If you are pregnant, have IBD or another gut disorder, or have been on long-term antibiotics or anticonvulsants (both can affect biotin status), discuss biotin supplementation with a clinician familiar with functional nutrient testing. Markedly elevated values, particularly in a child or with other organic acid abnormalities, warrant a referral to a metabolic specialist.